Targeting Covid-19 with a Therapeutic Interfering Particle

使用治疗性干扰粒子针对 Covid-19

• 批准号: 10383399
• 负责人: Raul Andino
• 金额: $ 29.59万
• 依托单位: ALEPH THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-05 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10383399
• 关键词: 2019-nCoV; A549; ACE2; Alpha Particles; Animal Experiments; Animal Model; Antiviral Agents; Body Weight; Brunhilde Virus; COVID-19; COVID-19 pandemic; Cell Culture Techniques; Cells; Clinical; Clinical Markers; Coxsackie Viruses; Data; Development; Disease; Drug or chemical Tissue Distribution; Enterovirus; Epithelial Cells; Funding; Future; Goals; Immune response; Infection; Influenza A virus; Innate Immune Response; K-18 conjugate; Lung; Measures; Messenger RNA; Monitor; Mus; Organoids; Process; Production; Public Health; RNA; Respiratory Disease; Rhinovirus; Safety; Therapeutic; Toxic effect; Transgenic Mice; Viral; Virus; Work; airway epithelium; base; efficacy evaluation; efficacy testing; experimental study; lipid nanoparticle; mouse model; novel strategies; novel therapeutics; particle; prevent; programs; prophylactic; respiratory; respiratory virus; treatment response

SUMMARY The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA-funded program and shows potent broad-spectrum activity across enteroviruses (Poliovirus Type 1 and 3, EVA71, and Coxsackievirus B3) as well as respiratory viruses EV-D68/HRV-87, Rhinovirus A16 and A1B, and Influenza A. Recently we have shown that eTIP1 significantly inhibits replication of SARS-CoV-2 both in cell culture and in K18-ACE2 mice. Given these results, it is critical to thoroughly evaluate eTIP1 as a potential agent against SARS-CoV-2. This work could be the starting point for a potential therapy or prophylactic agent against SARS-CoV-2. This would also represent a significant breakthrough for the development of a broad-spectrum antiviral agent that could potentially target current and future viral threats.

概括 严重急性呼吸冠状病毒2（SARS-COV-2）引起的19009年大流行 世界上最重要的公共卫生危机。考虑到这种疾病的前所未有的范围，这是至关重要的 探索减轻这一危机的新型策略。 Aleph Therapeutics和UCSF共同开发了ETIP1， 治疗性干扰粒子。 ETIP1是根据DARPA资助的计划开发的，并显示了有效的 跨肠病毒（脊髓灰质炎病毒1和3，EVA71和Coxsackievivirus B3）跨光谱活动也广泛。 作为呼吸道病毒EV-D68/HRV-87，鼻病毒A16和A1B以及流感A。 该ETIP1在细胞培养和K18-ACE2小鼠中都显着抑制SARS-COV-2的复制。给出 这些结果至关重要，将ETIP1彻底评估为针对SARS-COV-2的潜在药物。这项工作 可能是针对SARS-COV-2的潜在治疗或预防剂的起点。这也会 代表了可以开发广谱抗病毒剂的重大突破 潜在的目标当前和未来的病毒威胁。